UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 進行した腎不全における腎性全身性線維症／腎性線維化性皮膚症 nephrogenic systemic fibrosis nephrogenic fibrosing dermopathy in advanced renal failure
2. 肝胆道系のMRI magnetic resonance imaging of the hepatobiliary tract
3. 直腸癌治療前の局所の病期分類評価 pretreatment local staging evaluation for rectal cancer
4. 腎血管性高血圧の診断 establishing the diagnosis of renovascular hypertension
5. 皮膚リーシュマニア症の治療 treatment of cutaneous leishmaniasis

English Journal

Bifunctional Gd(III) and Tb(III) chelates based on a pyridine-bis(iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging.

Laurent S1, Vander Elst L, Galaup C, Leygue N, Boutry S, Picard C, Muller RN.
Contrast media & molecular imaging.Contrast Media Mol Imaging.2014 Jul-Aug;9(4):300-12. doi: 10.1002/cmmi.1576.
To study the physicochemical properties of lanthanide complexes derived from a bifunctional chelating agent based on a PMN-tetraacetic acid moiety {PMN-tetraacetic acid (1): [2,6-pyridinediylbis(methylene nitrilo)-tetraacetic acid]}, 4-carboxylic acid substituted pyridine derivative (2) was synthesi
PMID 24706614

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: Relationship to absorbed dose and time course after irradiation.

Okamoto D1, Nishie A2, Asayama Y1, Tajima T1, Ishigami K1, Kakihara D1, Nakayama T1, Ohga S1, Yoshitake T1, Shioyama Y1, Honda H1.
Magnetic resonance imaging.Magn Reson Imaging.2014 Jul;32(6):660-4. doi: 10.1016/j.mri.2014.02.019. Epub 2014 Feb 18.
PURPOSE: To evaluate if Gd-EOB-DTPA-enhanced MRI could identify liver tissue damage caused by radiation exposure in patients undergoing external beam radiation therapy.MATERIALS AND METHODS: We enrolled 11 patients who underwent Gd-EOB-DTPA-enhanced MRI during or after radiotherapy in which the radi
PMID 24666574

MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.

Ding G1, Zhang Z1, Chopp M2, Li L1, Zhang L1, Li Q1, Wei M1, Jiang Q3.
Neuroscience.Neuroscience.2014 Jun 20;271:1-8. doi: 10.1016/j.neuroscience.2014.04.025. Epub 2014 Apr 24.
The primary limitation of thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is the hemorrhagic risk. We tested AcSDKP (N-acetyl-seryl-aspartyl-lysyl-proline), as an auxiliary therapeutic agent, to reduce blood-brain barrier (BBB) disruption in a combination tPA thromb
PMID 24769225